Accueil   Diary - News   All news Tollys receives over €1.5 million deep tech financing from Bpifrance

Tollys receives over €1.5 million deep tech financing from Bpifrance

Support funding for breakthrough innovation will help company’s development in preparation for clinical trials in bladder cancer.


Lyon, France, July 6, 2020 – Tollys, the developer of TL-532, the first synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, today announces it has received over €1.5 million ($1.6M) from Bpifrance as part of its deep tech financing program. This program aims to increase support measures for breakthrough innovation in France and to strengthen the country’s competitive advantage in the field.

 

Read the press release